Deniz Akdis1, Ardan M Saguner1, Khooshbu Shah2, Chuanyu Wei2, Argelia Medeiros-Domingo3, Arnold von Eckardstein4,5, Thomas F Lüscher1,5, Corinna Brunckhorst1, H S Vincent Chen2, Firat Duru1,5. 1. Department of Cardiology, University Heart Center Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. 2. Development, Aging and Regeneration Program, Sanford-Burnham-Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd, La Jolla, CA 92037, USA. 3. Department of Cardiology, Inselspital Bern, Freiburgstrasse 10, 3010 Bern, Switzerland. 4. Department of Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. 5. Center for Integrative Human Physiology, University of Zurich, Winterthurerstr 190, 8057 Zurich, Switzerland.
Abstract
AIMS: Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is characterized by fibrofatty infiltration of the myocardium and ventricular arrhythmias that may lead to sudden cardiac death. It has been observed that male patients develop the disease earlier and present with more severe phenotypes as compared to females. Thus, we hypothesized that serum levels of sex hormones may contribute to major arrhythmic cardiovascular events (MACE) in patients with ARVC/D. METHODS AND RESULTS: The serum levels of five sex hormones, sex hormone-binding globulin, high sensitivity troponin T, pro-brain natriuretic peptide, cholesterol, triglycerides, insulin, and glucose were measured in 54 ARVC/D patients (72% male). Twenty-six patients (48%) experienced MACE. Total and free testosterone levels were significantly increased in males with MACE as compared to males with a favourable outcome, whereas estradiol was significantly lower in females with MACE as compared to females with a favourable outcome. Increased testosterone levels remained independently associated with MACE in males after adjusting for age, body mass index, Task Force criteria, ventricular function, and desmosomal mutation status. Furthermore, an induced pluripotent stem cell-derived ARVC/D cardiomyocyte model was used to investigate the effects of sex hormones. In this model, testosterone worsened and estradiol improved ARVC/D-related pathologies such as cardiomyocyte apoptosis and lipogenesis, strongly supporting our clinical findings. CONCLUSIONS: Elevated serum testosterone levels in males and decreased estradiol levels in females are independently associated with MACE in ARVC/D, and directly influence disease pathology. Therefore, determining the levels of sex hormones may be useful for risk stratification and may open a new window for preventive interventions. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is characterized by fibrofatty infiltration of the myocardium and ventricular arrhythmias that may lead to sudden cardiac death. It has been observed that male patients develop the disease earlier and present with more severe phenotypes as compared to females. Thus, we hypothesized that serum levels of sex hormones may contribute to major arrhythmic cardiovascular events (MACE) in patients with ARVC/D. METHODS AND RESULTS: The serum levels of five sex hormones, sex hormone-binding globulin, high sensitivity troponin T, pro-brain natriuretic peptide, cholesterol, triglycerides, insulin, and glucose were measured in 54 ARVC/D patients (72% male). Twenty-six patients (48%) experienced MACE. Total and free testosterone levels were significantly increased in males with MACE as compared to males with a favourable outcome, whereas estradiol was significantly lower in females with MACE as compared to females with a favourable outcome. Increased testosterone levels remained independently associated with MACE in males after adjusting for age, body mass index, Task Force criteria, ventricular function, and desmosomal mutation status. Furthermore, an induced pluripotent stem cell-derived ARVC/D cardiomyocyte model was used to investigate the effects of sex hormones. In this model, testosterone worsened and estradiol improved ARVC/D-related pathologies such as cardiomyocyte apoptosis and lipogenesis, strongly supporting our clinical findings. CONCLUSIONS: Elevated serum testosterone levels in males and decreased estradiol levels in females are independently associated with MACE in ARVC/D, and directly influence disease pathology. Therefore, determining the levels of sex hormones may be useful for risk stratification and may open a new window for preventive interventions. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Paul A van der Zwaag; Jan D H Jongbloed; Maarten P van den Berg; Jasper J van der Smagt; Roselie Jongbloed; Hennie Bikker; Robert M W Hofstra; J Peter van Tintelen Journal: Hum Mutat Date: 2009-09 Impact factor: 4.878
Authors: Ardan M Saguner; Alessandra Vecchiati; Samuel H Baldinger; Sina Rüeger; Argelia Medeiros-Domingo; Andreas S Mueller-Burri; Laurent M Haegeli; Patric Biaggi; Robert Manka; Thomas F Lüscher; Guy Fontaine; Etienne Delacrétaz; Rolf Jenni; Leonhard Held; Corinna Brunckhorst; Firat Duru; Felix C Tanner Journal: Circ Cardiovasc Imaging Date: 2014-02-10 Impact factor: 7.792
Authors: Anne-Christine Ruwald; Frank Marcus; N A Mark Estes; Mark Link; Scott McNitt; Bronislava Polonsky; Hugh Calkins; Jeffrey A Towbin; Arthur J Moss; Wojciech Zareba Journal: Eur Heart J Date: 2015-04-20 Impact factor: 29.983
Authors: Angeliki Asimaki; Sudhir Kapoor; Eva Plovie; Anne Karin Arndt; Edward Adams; ZhenZhen Liu; Cynthia A James; Daniel P Judge; Hugh Calkins; Jared Churko; Joseph C Wu; Calum A MacRae; André G Kléber; Jeffrey E Saffitz Journal: Sci Transl Med Date: 2014-06-11 Impact factor: 17.956
Authors: Aditya Bhonsale; Judith A Groeneweg; Cynthia A James; Dennis Dooijes; Crystal Tichnell; Jan D H Jongbloed; Brittney Murray; Anneline S J M te Riele; Maarten P van den Berg; Hennie Bikker; Douwe E Atsma; Natasja M de Groot; Arjan C Houweling; Jeroen F van der Heijden; Stuart D Russell; Pieter A Doevendans; Toon A van Veen; Harikrishna Tandri; Arthur A Wilde; Daniel P Judge; J Peter van Tintelen; Hugh Calkins; Richard N Hauer Journal: Eur Heart J Date: 2015-01-23 Impact factor: 29.983
Authors: Suet Nee Chen; Priyatansh Gurha; Raffaella Lombardi; Alessandra Ruggiero; James T Willerson; A J Marian Journal: Circ Res Date: 2013-11-25 Impact factor: 17.367
Authors: Perry M Elliott; Aris Anastasakis; Angeliki Asimaki; Cristina Basso; Barbara Bauce; Matthew A Brooke; Hugh Calkins; Domenico Corrado; Firat Duru; Kathleen J Green; Daniel P Judge; David Kelsell; Pier D Lambiase; William J McKenna; Kalliopi Pilichou; Alexandros Protonotarios; Jeffrey E Saffitz; Petros Syrris; Hari Tandri; Anneline Te Riele; Gaetano Thiene; Adalena Tsatsopoulou; J Peter van Tintelen Journal: Eur J Heart Fail Date: 2019-06-18 Impact factor: 15.534
Authors: Alain van Mil; Geerthe Margriet Balk; Klaus Neef; Jan Willem Buikema; Folkert W Asselbergs; Sean M Wu; Pieter A Doevendans; Joost P G Sluijter Journal: Cardiovasc Res Date: 2018-12-01 Impact factor: 10.787
Authors: Ibrahim El-Battrawy; Kim Schlentrich; Johanna Besler; Volker Liebe; Rainer Schimpf; Siegfried Lang; Katja E Odening; Christian Wolpert; Xiaobo Zhou; Martin Borggrefe; Ibrahim Akin Journal: Eur J Prev Cardiol Date: 2019-05-24 Impact factor: 7.804
Authors: Brian P Halliday; Ankur Gulati; Aamir Ali; Simon Newsome; Amrit Lota; Upasana Tayal; Vassilios S Vassiliou; Monika Arzanauskaite; Cemil Izgi; Kaushiga Krishnathasan; Arvind Singhal; Kayla Chiew; John Gregson; Michael P Frenneaux; Stuart A Cook; Dudley J Pennell; Peter Collins; John G F Cleland; Sanjay K Prasad Journal: Eur J Heart Fail Date: 2018-06-03 Impact factor: 15.534